| Product Includes | Product # | Quantity | Mol. Wt | Isotype/Source |
|---|---|---|---|---|
| β-Amyloid (D54D2) XP® Rabbit mAb | 8243 | 20 µl | 5 kDa | Rabbit IgG |
| Neurofilament-L (C28E10) Rabbit mAb | 2837 | 20 µl | 70 kDa | Rabbit IgG |
| Tau (Tau46) Mouse mAb | 4019 | 20 µl | 50-80 kDa | Mouse IgG1 |
| BACE1 (D10E5) Rabbit mAb | 5606 | 20 µl | 70 kDa | Rabbit IgG |
| APP/β-Amyloid (NAB228) Mouse mAb | 2450 | 20 µl | 100 to 140 kDa | Mouse IgG2a |
| α-Synuclein (Syn204) Mouse mAb | 2647 | 20 µl | 18 kDa | Mouse IgG2a |
| GSK-3α/β (D75D3) Rabbit mAb | 5676 | 20 µl | 51, 46 kDa | Rabbit IgG |
| Phospho-GSK-3α (Ser21) (36E9) Rabbit mAb | 9316 | 20 µl | 51 kDa | Rabbit |
| Anti-rabbit IgG, HRP-linked Antibody | 7074 | 100 µl | Goat | |
| Anti-mouse IgG, HRP-linked Antibody | 7076 | 100 µl | Horse |
Please visit cellsignal.com for individual component applications, species cross-reactivity, dilutions, protocols, and additional product information.
Description
The Alzheimer's Disease Antibody Sampler Kit provides an economical means of evaluating Alzheimer's Disease-related signaling. The kit contains enough primary and secondary antibodies to perform two western blot experiments per primary antibody.
Storage
Background
Alzheimer's Disease (AD) is one of the most common neurodegenerative diseases worldwide. Clinically, it is characterized by the presence of extracellular amyloid plaques and intracellular neurofibrillary tangles, which results in neuronal dysfunction and cell death. Central to this disease is the differential processing of the integral transmembrane glycoprotein Amyloid β (A4) precursor protein (APP) that exists as several isoforms (1). The amino acid sequence of APP contains the amyloid domain, which can be released by a two-step proteolytic cleavage (1). β-secretase (BACE) is an aspartic acid proteinase that catalyses the initial step in APP processing by cleaving and releasing a soluble, extracellular APP-β (sAPPβ) ectodomain and generating a membrane-bound, carboxy-terminal fragment consisting of 99 amino acids (CTF99). Additional processing of CTF99 by γ-secretase generates the amyloid β-peptide (Aβ) that forms aggregates in the brains of AD patients. BACE is an attractive target for inhibitors in AD therapy since it catalyses the first and rate limiting step in amyloidogenic APP processing (2). Pro-BACE-1 is synthesized in the ER before it is transported to the trans-Golgi network to undergo maturation (3). The extracellular deposition and accumulation of the released Aβ fragments and an α-synuclein fragment known as the non- Aβ fragment, form the main components of amyloid plaques in AD. GSK-3α regulates the production of Aβ peptides. Administration of therapeutic concentrations of lithium, a GSK-3 inhibitor, attenuates Aβ production by specifically inhibiting the cleavage of APP by γ-secretase, thereby blocking accumulation of Aβ peptides in the brains of mice that overproduce APP (4). AD is also characterized by the presence of neurofibrillary tangles. These tangles are the result of hyperphosphorylation and oligomerization of the microtubule associated protein Tau and lead to apoptosis of the neuron. In particular, phosphorylation of Tau Ser396 by GSK-3 or CDK5 destabilizes microtubules in AD (5,6). Additionally, neurofilaments are the major intermediate filaments found in neurons and consist of light (NFL), medium (NFM) and heavy (NFH) subunits (7). Accumulation of neurofilaments are found in many human neurological disorders including AD (7).
- Selkoe, D.J. (1996) J Biol Chem 271, 18295-8.
- Hunt, C.E. and Turner, A.J. (2009) FEBS J 276, 1845-59.
- Walter, J. et al. (2001) J Biol Chem 276, 14634-41.
- Phiel, C.J. et al. (2003) Nature 423, 435-9.
- Johnson, G.V. and Stoothoff, W.H. (2004) J Cell Sci 117, 5721-9.
- Bramblett, G.T. et al. (1993) Neuron 10, 1089-99.
- Al-Chalabi, A. and Miller, C.C. (2003) Bioessays 25, 346-55.
Background References
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
